Ribopro
Private Company
Total funding raised: $1.8M
Overview
RiboPro is a private, early-revenue stage CDMO and platform company focused on enabling mRNA-based therapeutics and vaccines. It provides a full suite of services from custom mRNA design and manufacturing to GMP production and LNP formulation, supported by its proprietary technology platforms. The company targets academic researchers, biotech startups, and pharmaceutical companies, positioning itself as a specialized partner in the rapidly growing RNA therapeutics sector. With a strong emphasis on quality, customer support, and internal R&D, RiboPro aims to accelerate the development of next-generation medicines.
Technology Platform
Proprietary mRNA design (RIBOPERFECT™), immune-stealth mRNA technology (RIBOSTEALTH™), LNP formulation expertise, and GMP manufacturing platform (RiboFlux™).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes with large, diversified CDMOs (e.g., Lonza, Catalent) building mRNA capacity, other specialized mRNA service providers, and the internal development capabilities of large pharmaceutical companies. Differentiation is based on deep mRNA-specific expertise, proprietary technology, and a full-service, integrated offering.